Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

Medicine and Dentistry

• Diabetes 100%
• Nephropathy 100%
• Randomized Clinical Trial 100%
• Cardiovascular Effect 100%
• Post-Hoc Analysis 100%
• Canagliflozin 100%
• Age 100%
• Kidney 100%
• Clinical Trial 100%
• Age Groups 25%
• Cardiovascular System 16%
• Serum 16%
• Diabetic Nephropathy 16%
• Renal Failure 16%
• Creatinine 16%
• Evaluation Study 16%
• Female 16%
• Death 16%
• Proportional Hazards Model 8%
• Senescence 8%
• Cardiovascular Disease 8%
• Intention-to-Treat Analysis 8%
• Development 8%
• Analysis 8%
• Man 8%
• Woman 8%
• Study Design 8%
• Placebo 8%
• Randomized Controlled Trial 8%

Nursing and Health Professions

• Diabetes Mellitus 100%
• Kidney Disease 100%
• Post Hoc Analysis 100%
• Clinical Evaluation 100%
• Canagliflozin 100%
• Kidney Failure 16%
• Creatinine Blood Level 16%
• Diabetic Nephropathy 16%
• Evaluation Study 16%
• Death 16%
• Intention to Treat Analysis 8%
• Proportional Hazards Model 8%
• Cardiovascular Disease 8%
• Placebo 8%
• Analysis 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetes Mellitus 100%
• Kidney Disease 100%
• Canagliflozin 100%
• Kidney Failure 16%
• Diabetic Nephropathy 16%
• Creatinine 16%
• Death 16%